Rheumatology Salaries 2025
Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
Read ArticleMedscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum.
Read ArticleEULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Read ArticleLa EULAR ha publicado una actualización de 2025 de las recomendaciones sobre actividad física para pacientes con osteoartritis (OA) y artritis reumatoide (AR).
Read ArticleThe future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market.
Read ArticleEl futuro de avacopan está en el aire. En abril, la FDA emitió una advertencia de seguridad sobre el medicamento, solicitando previamente a Amgen que retirara del mercado su fármaco para enfermedades raras, Tavneos. Ahora, parece haber más presión para retirarlo del mercado.
Read ArticleA current article in Nature Reviews Rheumatology has a patient boldly asking why we rheumatologists aren't more like her oncologists?
Read ArticleUn artículo reciente en Nature Reviews Rheumatology presenta a una paciente que pregunta audazmente por qué los reumatólogos no somos más como sus oncólogos.
Read ArticleFor decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
Read ArticleDurante décadas, el estándar de tratamiento en reumatología ha sido la terapia combinada, emparejando metotrexato (MTX) con un agente biológico avanzado o sintético para lograr resultados óptimos.
Read ArticleBy downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.